Last reviewed · How we verify
Investigator's choice of SOC
Investigator's choice of SOC is a Small molecule drug developed by CSPC Megalith Biopharmaceutical Co.,Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Investigator's choice of SOC |
|---|---|
| Sponsor | CSPC Megalith Biopharmaceutical Co.,Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study (PHASE1)
- Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy (PHASE2, PHASE3)
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (PHASE2, PHASE3)
- A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs (NA)
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (PHASE3)
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (PHASE3)
- Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigator's choice of SOC CI brief — competitive landscape report
- Investigator's choice of SOC updates RSS · CI watch RSS
- CSPC Megalith Biopharmaceutical Co.,Ltd. portfolio CI
Frequently asked questions about Investigator's choice of SOC
What is Investigator's choice of SOC?
Investigator's choice of SOC is a Small molecule drug developed by CSPC Megalith Biopharmaceutical Co.,Ltd..
Who makes Investigator's choice of SOC?
Investigator's choice of SOC is developed by CSPC Megalith Biopharmaceutical Co.,Ltd. (see full CSPC Megalith Biopharmaceutical Co.,Ltd. pipeline at /company/cspc-megalith-biopharmaceutical-co-ltd).
What development phase is Investigator's choice of SOC in?
Investigator's choice of SOC is in Phase 2.